Antiplatelet Therapy After Coronary Artery Bypass Surgery: Five-Year Follow-Up
Objective
To evaluate the impact of different antiplatelet strategies on patient outcomes following coronary artery bypass grafting.
Design
Five-year follow-up of the randomized DACAB trial (Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting).
Participants
500 patients aged 18-80 years who underwent elective coronary artery bypass grafting surgery and completed the DACAB trial.
Interventions
Patients were randomly assigned to receive either dual antiplatelet therapy, ticagrelor monotherapy, or aspirin monotherapy for one year post-surgery, with subsequent therapy based on standard care.
Main Outcome Measures
The primary outcome was the occurrence of major adverse cardiovascular events, including all-cause death, myocardial infarction, stroke, and coronary revascularization, analyzed using the intention-to-treat principle.
Results
At the five-year follow-up, dual antiplatelet therapy showed a significantly lower risk of major adverse cardiovascular events compared to aspirin monotherapy and ticagrelor monotherapy.
Conclusions
Using ticagrelor dual antiplatelet therapy for one year after surgery reduced the risk of major adverse cardiovascular events at five years following coronary artery bypass grafting when compared with aspirin monotherapy or ticagrelor monotherapy.
Trial Registration
NCT03987373 ClinicalTrials.gov NCT03987373.
Practical Solutions and Value
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians. In today’s healthcare environment, our mobile apps support scheduling, monitoring treatments, and telemedicine, streamlining operations and expanding services digitally. By leveraging AI, clinics can enhance workflows, improve patient outcomes, and reduce paper-based routines.
Learn More
Discover how we can help streamline and enhance clinical processes at aidevmd.com.
